Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms

Atherosclerosis

Volumn 159, Issue 2, 2001, Pages 297-306

  Plekhanova, Olga ^a   Parfyonova, Yelena ^a   Bibilashvily, Robert ^a   Domogatskii, Sergei ^a   Stepanova, Victoria ^a   Gulba, Dietrich C ^b   Agrotis, Alex ^c   Bobik, Alex ^c   Tkachuk, Vsevolod ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^b HUMBOLDT UNIVERSITY   (Germany)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Neointima; Plasminogen activators; Proliferation; Proteolysis; Vessel injury

Indexed keywords

NEUTRALIZING ANTIBODY; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; BALLOON CATHETER; CAROTID ARTERY INJURY; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; INTIMA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; SMOOTH MUSCLE FIBER; TISSUE REPAIR; TUNICA MEDIA;

ANALYSIS OF VARIANCE; ANGIOPLASTY, BALLOON; ANIMALS; BASE SEQUENCE; CAROTID ARTERY INJURIES; CELL DIVISION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR SEQUENCE DATA; PEPTIDE HYDROLASES; PROBABILITY; RATS; RATS, INBRED WKY; REFERENCE VALUES; REGENERATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUNICA INTIMA; URINARY PLASMINOGEN ACTIVATOR;

EID: 0035198124     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00511-1     Document Type: Article

References (43)

1. A cascade model for restenosis. A special case of atherosclerotic lesion progression
2. The vessel wall reaction in restenosis
3. Pathophysiology of restenosis: Interaction of thrombosis, hyperplasia, and/or remodeling
4. Smooth muscle migration in atherosclerosis and restenosis
5. Prevention of stenosis after vascular reconstruction: Pharmacological control of intima hyperplasia - A review
6. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor
7. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries
8. Regulator and role of urokinase plasminogen activator in vascular remodelling
9. Abnormalities in the fibrinolytic system of the vascular wall associated with atherosclerosis
10. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery
11. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice
12. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue receptor, and the plasminogen system
13. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries
14. Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells
15. Urokinase plasminogen activator induces smooth muscle cell migration: Key role of growth factor-like domain
16. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion
17. Inhibition of protein tyrosine kinases attenuates increases in expression of transforming growth factor β isoforms and their receptors following arterial injury
18. Urokinase plasminogen activator enhances intima and media growth and reduces lumen size in carotid arteries
19. Angiotensin-converting enzyme inhibition abolishes medial smooth muscle PDGF-AB biosynthesis and attenuates proliferation in injured carotid arteries: Relationships to neointima formation
20. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
21. Chemotactic effect of urokinase plasminogen activator: A major role for mechanisms independent of its proteolytic or growth factor domains
22. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis
23. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro
24. Redistriburion of von Willebrand factor in porcine carotid arteries after balloon angioplasty
25. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
26. Kinetics of cellular proliferation after arterial injury. I: Smooth muscle growth in the absence of endothelium
27. Significance of quiescent smooth muscle migration in the injured rat carotid artery
28. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease
29. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
30. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes
31. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells
32. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders
33. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms
34. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy
35. Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes
36. Native and non-glycosylated recombinant single-chain urokinase-type plasminogen activator are recognized by different receptor systems on rat parenchymal liver cells
37. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration
38. Basic fibroblast growth factor: Its role in the control of smooth muscle cell migration
39. Increased expression of membrane-type matrix metalloproteinase and preferential localization of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries
40. Regulated localization confers multiple functions on the protease plasminogen activator
41. Vascular remodelling and molecular biology: New concepts and therapeutic possibilities
42. Soluble transforming growth factor-b type II receptor inhibits negative remodeling, fibroblast transdifferentiation and intimal lesion formation but not endothelial growth
43. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries